Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Theravance’s Vibativ Adds Long-Sought Pneumonia Indication

This article was originally published in The Pink Sheet Daily

Executive Summary

Company has secured a new third-party manufacturer for the antibiotic and says it will relaunch the drug in the third quarter. FDA approval for telavancin’s use in hospital-acquired pneumonia comes four-and-a-half years after the original NDA submission for the supplemental claim.

Advertisement

Related Content

If At First You Don’t Succeed, Try Dispute Resolution
Theravance Re-Introduces Vibativ In The U.S. Independently (For Now)
Elan Makes A $1 Billion Theravance Royalty Play; What Will Investors Say?
GSK’s Breo Ellipta Approved With COPD Airflow Obstruction, Exacerbation Claims
Theravance To Split Into A Royalty Play and An R&D Company
Theravance’s Persistence On Telavancin Rewarded With Positive Cmte. Vote
Theravance’s Vibativ To Get FDA Panel Review For Hospital-Acquired Pneumonia
Theravance Gets To Market With Vibativ, But HAP Indication Could Be Pushed To 2010

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS075872

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel